Hackensack Meridian Children’s Health Pediatric Epileptologist Publishes Research on Clinical Use of Anti-Seizure Medication
Phase IV Research Published in Journal of Child Neurology
Pediatric epileptologist Eric Segal, M.D., is the lead author on new pediatric epilepsy research published in the January issue of the Journal of Child Neurology. Dr. Segal, a pediatric neurologist at Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center, and his colleagues conducted a Phase IV, multicenter, retrospective study showing the retention, dosing, efficacy, and safety of once-daily, oral anti-seizure medication perampanel (Fycompa) when administered to pediatric patients with epilepsy.
In the United States, perampanel is approved to treat focal seizures in patients who are four years old and older. It is also approved for use in combination with other medications to treat generalized tonic-clonic seizures in patients who are 12 years old and older.
Dr. Segal and his colleagues analyzed data obtained from medical records of 334 patients with epilepsy — 151 preadolescent patients aged 1 to <12 and 183 adolescent patients ages 12 to <18. The study, titled “PROVE — Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Interim Analysis in Pediatric Patients,” found that 42.5 percent of preadolescent patients and 55.7 adolescent patients remained on perampanel 24 months after initiating treatment.18.
The study also found that treatment-emergent adverse events occurred in 53 preadolescent patients (35.1 percent), with the most common adverse events being aggression, irritability and drowsiness. Seventy-eight adolescent patients (42.6 percent) experienced treatment-emergent adverse events, with the most common being drowsiness, aggression and dizziness.
“Our research shows that daily oral doses of perampanel are well-tolerated and have favorable retention rates for pediatric patients,” said Dr. Segal. “These findings provide real-world insight into the effectiveness and safety of perampanel therapy and can inform shared decision-making discussions between pediatric epileptologists, patients and parents.”
“Through ongoing study of various epilepsy medications, Dr. Segal and his colleagues are able to advance our understanding of how medications can be used effectively in clinical practice and work toward developing and updating evidence-based therapeutic guidelines,” said Judy Aschner, M.D., physician-in-chief, Pediatrics, Hackensack Meridian Children’s Health.
Learn more about our advancements in pediatric neurology and neurosurgery.